勃林格殷格翰的思力华可用于治疗什么病症？

What conditions can Boehringer Ingelheim be used to treat? Slivar is a long-acting anticholinergic drug developed by Boehringer Ingelheim. It is suitable for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and can help adult patients with chronic obstructive pulmonary disease (COPD) breathe easier.

Boehringer Ingelheim is a pharmaceutical company specializing in human biopharmaceutical chemistry and animal health products and the world's largest privately held pharmaceutical company. Human pharmaceuticals are Boehringer Ingelheim's largest business, with revenue from the human pharmaceuticals business reaching 12.6 billion euros, accounting for 72% of the group's total revenue. In 2014, Slivar, developed by Boehringer Ingelheim, was approved for marketing in my country, bringing a more efficient, safe and convenient new treatment option to COPD patients.

In research trials, at the experimental research center, Slihua has a high affinity with receptors in human airways, and dissociates slowly from muscarinic M1 and M3 receptors, and can block cholinergic nerve-mediated contraction of bronchial smooth muscle for a long time. However, Slava dissociates from the muscarinic M2 receptor quite quickly, thus showing unique kinetic selectivity for M1 and M3 receptors.

Siliva spray is a colorless, clear liquid that can only be used by inhalation. The recommended dose for adults is to inhale once a day through the Respimat inhaler device at the same time, taking 2 puffs each time. Be careful not to overdose. For elderly patients, there is no need to adjust the dosage. Patients with renal insufficiency and hepatic insufficiency can also use it at the recommended dosage, but it is best to do relevant monitoring. The safety of the drug is unknown and its use in pediatric patients under 18 years of age is not recommended.

The above is the introduction of Boehringer Ingelheim’s indication-related information. I hope it will be helpful to you.

Recommended related hot articles: /newsDetail/88856.html